Literature DB >> 14657065

Survival after pancreas transplantation in patients with diabetes and preserved kidney function.

Jeffrey M Venstrom1, Maureen A McBride, Kristina I Rother, Boaz Hirshberg, Trevor J Orchard, David M Harlan.   

Abstract

CONTEXT: Solitary pancreas transplantation (ie, pancreas alone or pancreas-after-kidney) for diabetes mellitus remains controversial due to procedure-associated morbidity/mortality, toxicity of immunosuppression, expense, and unproven effects on the secondary complications of diabetes. Whether transplantation offers a survival advantage over conventional therapies for diabetes is unknown.
OBJECTIVE: To determine the association between solitary pancreas transplantation and survival in patients with diabetes and preserved kidney function. DESIGN, SETTING, AND PATIENTS: Retrospective observational cohort study conducted at 124 transplant centers in the United States, in 11 572 patients with diabetes mellitus on the waiting list for pancreas transplantation (pancreas alone, pancreas-after-kidney, or simultaneous pancreas-kidney) at the United Network for Organ Sharing/Organ Procurement and Transplantation Network between January 1, 1995, and December 31, 2000. All patients receiving a multiorgan (other than simultaneous pancreas-kidney) transplant were excluded, as were those listed for solitary pancreas transplantation who had a serum creatinine level greater than 2 mg/dL (176.8 micromol/L) at time of listing, or who ultimately received a simultaneous pancreas-kidney transplant. MAIN OUTCOME MEASURE: All-cause mortality within 4 years following transplantation (or within a comparable time on the waiting list for the group not undergoing transplantation).
RESULTS: Overall relative risk of all-cause mortality for transplant recipients (compared with patients awaiting the same procedure) over 4 years of follow-up was 1.57 (95% confidence interval [CI], 0.98-2.53; P =.06) for pancreas transplant alone, 1.42 (95% CI, 1.03-1.94; P =.03) for pancreas-after-kidney transplant, and 0.43 (95% CI, 0.39-0.48) for simultaneous pancreas-kidney transplant. Transplant patient 1- and 4-year survival rates were 96.5% and 85.2% for pancreas transplant alone, respectively, and 95.3% and 84.5% for pancreas-after-kidney transplant, while 1- and 4-year survival rates for patients on the waiting list were 97.6% and 92.1% for pancreas transplant alone, respectively, and 97.1% and 88.1% for pancreas-after-kidney transplant.
CONCLUSION: From 1995-2000, survival for those with diabetes and preserved kidney function and receiving a solitary pancreas transplant was significantly worse compared with the survival of waiting-list patients receiving conventional therapy.

Entities:  

Mesh:

Year:  2003        PMID: 14657065     DOI: 10.1001/jama.290.21.2817

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  61 in total

1.  Islet transplantation as a treatment for diabetes.

Authors:  David M Harlan; Kristina I Rother
Journal:  N Engl J Med       Date:  2004-05-13       Impact factor: 91.245

2.  Challenges facing islet transplantation for the treatment of type 1 diabetes mellitus.

Authors:  Kristina I Rother; David M Harlan
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

Review 3.  Islet versus pancreas transplantation in type 1 diabetes: competitive or complementary?

Authors:  Barbara Ludwig; Stefan Ludwig; Anja Steffen; Hans-Detlev Saeger; Stefan R Bornstein
Journal:  Curr Diab Rep       Date:  2010-12       Impact factor: 4.810

4.  The cardinal features of recurrent autoimmunity in simultaneous pancreas-kidney transplant recipients.

Authors:  Boaz Hirshberg
Journal:  Curr Diab Rep       Date:  2010-10       Impact factor: 4.810

Review 5.  State of the art of clinical islet transplantation and novel protocols of immunosuppression.

Authors:  A M James Shapiro
Journal:  Curr Diab Rep       Date:  2011-10       Impact factor: 4.810

6.  Report from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell Replacement.

Authors:  Stephen T Bartlett; James F Markmann; Paul Johnson; Olle Korsgren; Bernhard J Hering; David Scharp; Thomas W H Kay; Jonathan Bromberg; Jon S Odorico; Gordon C Weir; Nancy Bridges; Raja Kandaswamy; Peter Stock; Peter Friend; Mitsukazu Gotoh; David K C Cooper; Chung-Gyu Park; Phillip OʼConnell; Cherie Stabler; Shinichi Matsumoto; Barbara Ludwig; Pratik Choudhary; Boris Kovatchev; Michael R Rickels; Megan Sykes; Kathryn Wood; Kristy Kraemer; Albert Hwa; Edward Stanley; Camillo Ricordi; Mark Zimmerman; Julia Greenstein; Eduard Montanya; Timo Otonkoski
Journal:  Transplantation       Date:  2016-02       Impact factor: 4.939

7.  The time interval between kidney and pancreas transplantation and the clinical outcomes of pancreas after kidney transplantation.

Authors:  Fu L Luan; Mallika Kommareddi; Diane M Cibrik; Millie Samaniego; Akinlolu O Ojo
Journal:  Clin Transplant       Date:  2011-10-17       Impact factor: 2.863

Review 8.  Assessment of islet function following islet and pancreas transplantation.

Authors:  Emily C Dy; David M Harlan; Kristina I Rother
Journal:  Curr Diab Rep       Date:  2006-08       Impact factor: 4.810

9.  Porcine pancreas extracellular matrix as a platform for endocrine pancreas bioengineering.

Authors:  Sayed-Hadi Mirmalek-Sani; Giuseppe Orlando; John P McQuilling; Rajesh Pareta; David L Mack; Marcus Salvatori; Alan C Farney; Robert J Stratta; Anthony Atala; Emmanuel C Opara; Shay Soker
Journal:  Biomaterials       Date:  2013-04-10       Impact factor: 12.479

10.  Transplantation for type I diabetes: comparison of vascularized whole-organ pancreas with isolated pancreatic islets.

Authors:  Adam Frank; Shaoping Deng; Xiaolun Huang; Ergun Velidedeoglu; Yong-Suk Bae; Chengyang Liu; Peter Abt; Robert Stephenson; Muhammad Mohiuddin; Thav Thambipillai; Eileen Markmann; Maral Palanjian; Marty Sellers; Ali Naji; Clyde F Barker; James F Markmann
Journal:  Ann Surg       Date:  2004-10       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.